Kairos Pharma, Ltd. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Kairos Pharma, Ltd.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Kairos Pharma, Ltd. or its management. Kairos Pharma, Ltd. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Analysts
Firm Analyst
EF Hutton Jason Kolbert
Overcoming Hurdles in Immune Suppression and Drug ResistanceOpens in a new window
D. Boral Capital Jason Kolbert
Prostate Cancer Trial Expands Beyond CedarsOpens in a new window
Department of Defense Funds Kairos Pharma’s ENV205 Research, Strengthening Drug Development PipelineOpens in a new window
Evidence for KROS 101 and KROS 401 in Melanoma and GlioblastomaOpens in a new window
Kairos Highlights Breakthrough in Overcoming EGFR Resistance in Lung CancerOpens in a new window
ASCO Data on KROS101 a Small Molecule GITR Ligand AgonistOpens in a new window
Promising Interim P2 Data for ENV105Opens in a new window
Kairos PharmaOpens in a new window
Kairos Pharma Highlights Interim Phase 2 Data for ENV-105 in Advanced Prostate Cancer Opens in a new window
Kairos Shareholder Update: Advancing ENV105 and Expanding Oncology Portfolio Opens in a new window
Rodman and Renshaw Tony Butler
KAPA: The Critical Moment to Target Cancer Drug ResistanceOpens in a new window
KAPA: Pre-Clinical Examination of an Antibody (Carotuximab) to “Re-sensitize” Osimertinib-resistant NSCLC PatientsOpens in a new window
Maxim Group Jason McCarthy
2Q25 Review & Outlook: Catalyst Approaches with Interim Efficacy Data from P2 Prostate Cancer Study Expected in SeptemberOpens in a new window
Targeting CD105 Could Extend SOC Prostate and Lung Cancer Treatments – Initiating Coverage with a Buy Rating and $4 PTOpens in a new window
Positive Preclinical Data for KROS101 at Ongoing ASCO Meeting; P2 Interim Data in Prostate CancerOpens in a new window
Positive Safety Data from P2 Prostate Cancer Trial for ENV105 Sends Shares Up Sharply; Interim Efficacy Data due in SeptemberOpens in a new window
Small N Value but Compelling Data for ENV-105 in Prostate Cancer; KOL Webcast 5pm ET TodayOpens in a new window
Upcoming ESMO Presentation to Highlight ENV-105 P2 Prostate Cancer Data; Initial NSCLC P1 Data Expected by YE25Opens in a new window
HC Wainwright Joe Pantginis
KAPA: Attacking Cancer Rx Resistance and Boosting Immune Function; Initiating at Buy and $12 PTOpens in a new window
KAPA: 2024 Results; Oncology Pipeline Poised for Multiple Readouts; Initial Phase 2 ENV-105 mCRPC Data Expected 1H25Opens in a new window
Nice Check From DoD to Secure Advancement of ENV-105 in EGFR-driven NSCLC; Initial Phase 1 Data Expected by YE25Opens in a new window
ENV-105 Advances in mCRPC Phase 2 Study With Positive Safety Update; Interim Efficacy Data Expected 3Q25Opens in a new window
E2Q25 Results; ENV-105 Phase 2 Study Continues to Advance; Interim Efficacy Data Expected 3Q25Opens in a new window
Positive Interim Phase 2 Data For ENV-105 in mCRPC Builds Compelling Profile and Extended PFS Benefit Opens in a new window